Opportunities and risks associated with external comparator cohorts in clinical drug development in hematology
Open Access
- 19 November 2025
- journal article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 199
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trialsBlood Cancer Journal, 2025
- Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World SettingEuropean Journal of Haematology, 2025
- Demonstration of Major Therapeutic Advantage From a Review of EU Conditional Marketing Authorizations in Oncology and HematologyClinical Pharmacology & Therapeutics, 2025
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialThe Lancet, 2024
- The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide studyLeukemia & Lymphoma, 2024
- Consumer attitudes, barriers and facilitators to sharing clinical data for research purposes: Results from a focus group synthesisHeliyon, 2024
- Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 yearsBritish Journal of Haematology, 2021
- Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomasBritish Journal of Haematology, 2018
- Addressing the challenges of cross‐jurisdictional data linkage between a national clinical quality registry and government‐held health dataAustralian and New Zealand Journal of Public Health, 2016
- Health Services Research and Data Linkages: Issues, Methods, and Directions for the FutureHealth Services Research, 2010